<DOC>
	<DOCNO>NCT02195375</DOCNO>
	<brief_summary>The purpose study investigate whether flutiform® effective safe treatment chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Flutiform® Compared With Seretide® Treatment COPD</brief_title>
	<detailed_description>A multi-centre , randomised , double-blind , double dummy , active-controlled , parallel-group study male female subject conduct assess efficacy safety flutiform treatment COPD . Subjects randomise one three treatment group 1:1:1 ratio . Throughout study subject assess mixture symptom base lung function measurement monitor progress study .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Inclusion : 1 . Male Female subject age ≥ 40 year screen visit . 2 . Diagnosis COPD 3 . Willing able replace current COPD therapy study medication . 4 . Able demonstrate correct use pMDI without spacer Accuhaler . 5 . Willing able attend study visit complete study assessment . 6 . Able provide sign informed consent . Exclusion : 1 . Ongoing moderate severe exacerbation COPD 2 week screen . 2 . Current diagnosis asthma . 3 . Documented evidence α1antitrypsin deficiency underlie cause COPD . 4 . Other active respiratory disease active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , pulmonary hypertension , interstitial lung disease , cystic fibrosis , bronchiolitis obliterans . 5 . Previous lung resection . 6 . Use longterm oxygen therapy ( LTOT ) mechanical ventilation . Note : LTOT define &gt; 15 hour use per day 7 . Chest Xray CT scan reveals evidence clinically significant abnormality believe due COPD . 8 . Evidence uncontrolled cardiovascular disease . 9 . Evidence clinically significant renal , hepatic , gastrointestinal , psychiatric disease . 10 . Current malignancy previous history cancer remission &lt; 5 year ( basal cell squamous cell carcinoma skin resect exclude ) . 11 . Clinically significant sleep apnoea require use continuous positive airway pressure ( CPAP ) device noninvasive positive pressure ventilation ( NIPPV ) device . 12 . Participation acute phase pulmonary rehabilitation programme within 4 week prior screen study . 13 . Known suspected history drug alcohol abuse last 2 year . 14 . Requiring treatment prohibit concomitant medication . 15 . Known suspected hypersensitivity study drug excipients . 16 . Received investigational drug within 30 day screen visit ( 12 week oral injectable steroid ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>FEV1 ≤ 50 %</keyword>
</DOC>